Hepatitis C – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Hepatitis C – Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hepatitis C
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AB Pharma LtdAbbVie Inc
Acceleromics SL
Altesa Biosciences Inc
Apexian Pharmaceuticals Inc
Aragon Institute of Health Sciences
Ascletis Pharma Inc
Asterivir SA
Atea Pharmaceuticals Inc
Auro Vaccines LLC
Beta Pharma Inc
Biotron Ltd
Bolder Biotechnology Inc
Bristol-Myers Squibb Co
Bugworks Research Inc
Burnet Institute
Center for Genetic Engineering and Biotechnology
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Children's Hospital of Philadelphia
Chinese Academy of Medical Sciences and Peking Union Medical College
Cocrystal Pharma Inc
ConserV Bioscience Ltd
DEKK-TEC Inc
Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
Eagle Pharmaceuticals Inc
Ennaid Therapeutics LLC
Escient Pharmaceuticals Inc
ethris GmbH
Eyam Vaccines and Immunotherapeutics Ltd
Francois Rabelais University of Tours
French National Institute of Health and Medical Research
Galactica Biotech Ltd
GeneCure Biotechnologies LLC
GeneOne Life Science Inc
Genoscience Pharma
Gilead Sciences Inc
GSK plc
HEC Pharma Co Ltd
Helmholtz Centre for Infection Research
ImmunoBiology Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
iQur Ltd
J2H Biotech
Kaohsiung Medical University
Los Alamos National Laboratory
Loyola University Medical Center
Medivir AB
Merck & Co Inc
MetalloPharm LLC
NeuImmune Inc
Novalex Therapeutics Inc
Ohio State University
Okayama University
Osaka University
Palisades Therapeutics
Pharco Pharmaceuticals Inc
PharmaEssentia Corp
Presidio Pharmaceuticals Inc
Princeton University
Resilience Biotechnologies Inc
Riboscience LLC
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Shanghai Newsummit Biopharma Co Ltd
Shanghai Tangrun Pharmaceuticals Co Ltd
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
Spanish National Research Council
Statera Biopharma Inc
Sudarshan Biotech Pvt Ltd
TaiGen Biotechnology Co Ltd
Tetranov International Inc
The Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
Toray Industries Inc
U.S. National Institutes of Health
UBI Pharma Inc
University of California Los Angeles
University of California San Diego
University of Glasgow
University of Michigan
University of North Carolina at Chapel Hill
University of Paris-Est
University of Pittsburgh
University of Southampton
University of Strasbourg
University of the Witwatersrand
Uppsala University
Uvax Bio LLC
Vanderbilt University
Vanworld Pharmaceutical (Rugao) Company Ltd
Vertex Pharmaceuticals Inc
Virocovax
Zylacta Corp